Immune Pharmaceuticals Inc. (NASDAQ:IMNP) was the target of a significant increase in short interest in September. As of September 29th, there was short interest totalling 1,502,832 shares, an increase of 39.3% from the September 15th total of 1,079,060 shares. Currently, 15.4% of the company’s stock are short sold. Based on an average trading volume of 1,398,993 shares, the days-to-cover ratio is currently 1.1 days.

Immune Pharmaceuticals (NASDAQ:IMNP) opened at 1.60 on Friday. The company’s 50-day moving average is $1.27 and its 200 day moving average is $1.96. Immune Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $7.15. The company’s market capitalization is $16.92 million.

A hedge fund recently raised its stake in Immune Pharmaceuticals stock. Susquehanna International Group LLP raised its stake in shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) by 41.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,805 shares of the biopharmaceutical company’s stock after purchasing an additional 20,488 shares during the quarter. Susquehanna International Group LLP owned approximately 0.69% of Immune Pharmaceuticals worth $215,000 at the end of the most recent reporting period. 3.39% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Immune Pharmaceuticals Inc. (IMNP) Sees Significant Growth in Short Interest” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/14/immune-pharmaceuticals-inc-imnp-sees-significant-growth-in-short-interest.html.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.